西罗莫司洗脱铁基生物可吸收支架与依维莫司洗脱钴铬支架用于PCI的随机试验(IRONMAN II)
IRONMAN-II是一项在中国36个中心开展的前瞻性、多中心、单盲、非劣效随机试验,纳入518例有心肌缺血且1或2处新生靶病变的冠心病患者,1:1随机接受西罗莫司洗脱铁基生物可吸收支架(IBS)或钴铬依维莫司洗脱支架(CoCr-EES)。2年节段内晚期管腔丢失(LLL)IBS为0.28(0.52)mm,CoCr-EES为0.23(0.43)mm,差异0.08 mm(95%CI -0.02至0.18),非劣效P=0.03;QFR和OCT流面积亦非劣效。两组临床事件率相当,但IBS组非缺血驱动的血运重建率较高。
要点
- IBS在2年节段内LLL、QFR和OCT流面积方面非劣效于CoCr-EES。
- 两组靶病变失败、患者导向复合终点、死亡或心肌梗死率无显著差异。
- IBS组无支架血栓形成,但二分类再狭窄和血运重建率较高,多为非缺血驱动。
核心结论
- 西罗莫司洗脱IBS在2年节段内LLL、QFR和OCT衍生流面积方面非劣效于CoCr-EES,临床事件率总体相当,但IBS组非缺血驱动血运重建率较高。
研究设计与样本
- IRONMAN-II为前瞻性、多中心、单盲、非劣效随机试验,在中国36个中心开展,2022年3月10日至12月13日随机518例患者至IBS组(n=259)或CoCr-EES组(n=259)。
- 纳入标准为有心肌缺血且1或2处新生靶病变;前25对参与者行OCT检查;临床随访至5年,2年时行血管造影和OCT随访。
- 主要终点为2年血管造影节段内晚期管腔丢失(LLL)。
主要发现
- 2年节段内LLL:IBS组0.28(0.52)mm,CoCr-EES组0.23(0.43)mm,差异0.08 mm(95%CI -0.02至0.18),非劣效P=0.03。
- 平均QFR:IBS组0.90(0.13),CoCr-EES组0.92(0.09),差异-0.02(95%CI -0.04至0),非劣效P=0.05。
- 平均OCT流面积:IBS组6.92(3.48)mm²,CoCr-EES组6.64(2.44)mm²,差异0.27(95%CI -0.09至0.63),非劣效P<0.0001。
- 2年靶病变失败:IBS组7.4%,CoCr-EES组5.4%(HR 1.37;95%CI 0.69-2.73;P=0.37);患者导向复合终点、死亡或心肌梗死率组间无显著差异。
- IBS组无支架血栓形成,CoCr-EES组发生1例支架血栓;IBS组二分类再狭窄和血运重建率较高,但多数事件非缺血驱动。
临床怎么用
- 对于符合IRONMAN-II入选标准的冠心病患者,IBS可作为CoCr-EES的替代选择,2年造影和生理学指标非劣效。
- 需注意IBS组非缺血驱动血运重建率较高,临床决策时应结合病变特征和患者意愿。
- IBS完全吸收后的远期获益尚需更长期随访验证。
局限性
- 随访时间仅2年,不足以评估IBS完全吸收后的晚期获益。
- 研究在中国36个中心进行,结果外推需考虑人群和操作差异。
- OCT亚组仅前25对参与者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The novel thin-strut sirolimus-eluting iron bioresorbable scaffold (IBS) demonstrated safety and efficacy in a nonrandomized first-in-human study. OBJECTIVES: The objective of this study was to compare the IBS with contemporary metallic cobalt chromium everolimus-eluting stents (CoCr-EES) in patients with coronary artery disease. METHODS: IRONMAN-II was a prospective, multicenter, single-blinded, noninferiority randomized trial across 36 centers in China. Eligible patients had myocardial ischemia and 1 or 2 de novo target lesions. Patients were randomly assigned (1:1) to IBS or CoCr-EES, with allocation masked. Optical coherence tomography (OCT) was performed in the first 25 participant pairs. Clinical follow-up was scheduled at 1, 6, and 12 months, and annually to 5 years, with angiographic and OCT follow-up at 2 years. The primary endpoint was 2-year angiographic in-segment late lumen loss (LLL). Powered secondary endpoints included target vessel quantitative flow ratio (QFR) and OCT-derived cross-sectional mean flow area. Other secondary endpoints included target lesion failure (cardiac death, target vessel myocardial infarction [MI], or ischemia-driven target vessel revascularization), the patient-oriented composite endpoint (all-cause death, MI, or any revascularization), their individual components, and device thrombosis. RESULTS: Between March 10 and December 13, 2022, 518 patients were randomized to IBS (n = 259) or CoCr-EES (n = 259). At 2 years, lesion-level in-segment LLL was 0.28 (0.52) mm with IBS and 0.23 (0.43) mm with CoCr-EES (difference: 0.08 mm; 95% CI: -0.02 to 0.18; Pnoninferiority = 0.03). Mean QFR was 0.90 (0.13) with IBS and 0.92 (0.09) with CoCr-EES (difference: -0.02; 95% CI: -0.04 to 0; Pnoninferiority = 0.05). Mean OCT flow area was 6.92 (3.48) mm2 with IBS and 6.64 (2.44) mm2 with CoCr-EES (difference: 0.27; 95% CI: -0.09 to 0.63; Pnoninferiority < 0.0001). Two-year target lesion failure occurred in 7.4% of IBS patients and 5.4% of CoCr-EES patients (HR: 1.37; 95% CI: 0.69-2.73; P = 0.37). No significant between-group differences in the rates of patient-oriented composite endpoint, death, or MI were present between the 2 groups. No scaffold thromboses occurred in the IBS group, whereas 1 stent thrombosis occurred with CoCr-EES. Binary restenosis and revascularization rates were higher with IBS, however, most such events were non-ischemia-driven. CONCLUSIONS: In IRONMAN-II, the sirolimus-eluting IBS was noninferior to CoCr-EES for 2-year in-segment LLL, QFR, and OCT-derived flow area. Clinical event rates were also comparable between groups although non-ischemia-driven revascularization rates were higher after IBS. Longer-term follow-up is necessary to demonstrate whether late benefits are realized after complete IBS resorption. (A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease; NCT05206084).
引用
- Gao R, Song L, Fu G, et al. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). J Am Coll Cardiol. 2026. PMID: 41670556. doi:10.1016/j.jacc.2025.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。